Tagraxofusp Alone and in Combination with Ruxolitinib for Treatment of Myeloproliferative Neoplasms
Evaluation of Tagraxofusp(SL-401) Alone and in Combination with Ruxolitinib for…
Results from Clinical Trial of Tagraxofusp in Patients with Intermediate or High Risk R/R MF
Results from Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with…
Tagraxofusp in Combination with POM/DEX in Relapsed or Refractory Multiple Myeloma
Results from Phase 1/2 Trial of Tagraxofusp in Combination with Pomalidomide…
CD123+ plasmacytoid dendritic cells (pDCs) from SSc patients are susceptible to tagraxofusp
CD123+ plasmacytoid dendritic cells (pDCs) from SSc patients are susceptible to…
Outcomes of Tagraxofusp (SL-401) in Older Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Outcomes of Tagraxofusp (SL-401) in Older Patients with Blastic Plasmacytoid…
Interim Results from a Phase 1 Trial of SL-801, a Novel XPO1 Inhibitor, in Patients with Advanced Solid Tumors
Interim Results from a Phase 1 Trial of SL-801, a Novel XPO1 Inhibitor, in…
Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Relapsed/Refractory Chronic Myelomonocytic Leukemia (CMML)
Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in…
Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate or High Risk Relapsed/Refractory Myelofibrosis
Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in…
Results of Pivotal Phase 2 Trial of Tagraxofusp (SL-401) in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Results of Pivotal Phase 2 Trial of Tagraxofusp (SL-401) in Patients with…
CD123+ plasmacytoid dendritic cells (pDCs) from systemic sclerosis patients are susceptible to the cytotoxic activity of tagraxofusp, a CD123-targeted therapy
CD123+ plasmacytoid dendritic cells (pDCs) from systemic sclerosis patients are…